Adherence to antihypertensive medication and cardiovascular disease events in hypertensive patients: a dose-response Meta-analysis of 2,769,700 participants in cohort study.

Abstract

BACKGROUND\nRecently, many studies have investigated the association between adherence to antihypertensive medication (AHM) and risk of cardiovascular disease (CVD) events for hypertensive patients; however, the results varied by different studies.\n\n\nAIMS\nThe purpose of our meta-analysis was to explore the comprehensively summarized association between AHM adherence and risk of CVD events in hypertensive patients from cohort studies.\n\n\nDESIGN\nA dose-response meta-analysis.\n\n\nMETHODS AND RESULTS\nWe conducted a systematic search in 2 databases (PubMed and Embase) from 1974 to December 15, 2019 to identify English language reports that assessed the association of AHM adherence with risk of CVD events in cohort studies. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were estimated by using a fixed- or random-effects model. Restricted cubic splines were used to evaluate the possible linear or nonlinear association.\n\n\nRESULTS\nWe included 16 cohort studies with 2,769,700 participants in the present meta-analysis. The pooled RR of CVD events was 0.66 (95% CI, 0.56-0.78, I2 =98.6%) for the highest versus lowest AHM adherence categories. We found a linear dose-response association of AHM adherence and CVD events (Pnonlinearity =0.887), each 20% increase in AHM adherence was associated with a 13% reduced risk of CVD events (RR 0.87, 95% CI 0.83-0.92, I2 =98.2%) in hypertensive patients.\n\n\nCONCLUSION\nHigh AHM adherence has a protective effect on CVD events for hypertensive patients, and improving medication adherence may provide long-term CVD benefits.